Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclic nucleotides and phosphodiesterases and airway function

P J Barnes1

  • 1Dept of Thoracic Medicine, National Heart and Lung Institute, London, UK.

The European Respiratory Journal
|March 1, 1995
PubMed
Summary

Phosphodiesterases (PDEs) regulate cyclic nucleotides like cAMP and cGMP, crucial for airway function. PDE IV inhibitors show promise as anti-inflammatory asthma treatments, with clinical trials underway.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid resistance in asthma.

American journal of respiratory and critical care medicine·1995
Same author

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

The Journal of experimental medicine·1995
Same author

Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

Molecular pharmacology·1995
Same author

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages.

The American journal of physiology·1995
Same author

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction.

Thorax·1995

Area of Science:

  • Biochemistry
  • Pharmacology
  • Respiratory Medicine

Background:

  • Cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), are key regulators of airway smooth muscle tone and inflammatory cell activity.
  • Intracellular levels of cAMP and cGMP are modulated by phosphodiesterases (PDEs), a diverse enzyme family with multiple members across different isoenzyme families.
  • Specific PDEs, such as PDE III, IV, and V, are implicated in the breakdown of cAMP and cGMP in airway smooth muscle and inflammatory cells.

Purpose of the Study:

  • To investigate the role of phosphodiesterases (PDEs) in regulating cyclic nucleotide signaling in the airways.
  • To explore the potential of selective PDE inhibitors, particularly PDE IV inhibitors, as anti-inflammatory therapeutic agents for asthma.

Main Methods:

  • Review of existing literature on PDE families, their substrates (cAMP and cGMP), and their roles in airway physiology and pathophysiology.
  • Analysis of experimental studies investigating the effects of selective PDE inhibitors on airway smooth muscle tone and inflammatory cell function.
  • Consideration of ongoing clinical trials evaluating PDE IV inhibitors for asthma treatment.

Main Results:

  • PDE III and IV are critical for cAMP breakdown, with PDE III influencing airway smooth muscle and PDE IV impacting inflammatory cells (mast cells, macrophages, eosinophils, T-lymphocytes, epithelial cells).
  • PDE V regulates cGMP breakdown in airway and vascular smooth muscle.
  • Experimental data suggest that selective PDE IV inhibitors possess anti-inflammatory properties beneficial for asthma management.

Conclusions:

  • Phosphodiesterases play a significant role in airway smooth muscle and inflammation, making them potential therapeutic targets.
  • PDE IV inhibitors demonstrate therapeutic potential for asthma due to their anti-inflammatory effects on key airway cells.
  • Further clinical investigation of PDE IV inhibitors in asthma is warranted and currently in progress.

Related Experiment Videos